<DOC>
	<DOCNO>NCT00896155</DOCNO>
	<brief_summary>Two hundred sixty patient breast cancer accrue study . After inclusion study , patient randomize two arm . Arm 1 receive Tamoxifen give concurrently radiotherapy Arm 2 radiotherapy give follow tamoxifen sequentially . The patient stratify follow factor : ) BCS ( Breast conservative surgery ) versus MRM ( modify radical mastectomy ) b ) central lung distance ( CLD ) &gt; 2 cm . Patients arm continue tamoxifen period 5 year . The patient evaluate high-resolution compute tomography ( HRCT ) ( baseline 2 year ) , serum transform growth factor ( TGF ) beta level ( baseline 6 month ) diethylenetriaminepentaacetic acid ( DTPA ) aerosol clearance half life ( baseline 6 month ) .</brief_summary>
	<brief_title>Trial Concurrent Versus Sequential Tamoxifen With Radiotherapy Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Patients large operable lesion ( pT/cT &gt; 5 cm ) locally advance breast cancer undergo modified radical mastectomy breast conservative surgery ( BCS ) need adjuvant post operative radiotherapy Patients post mastectomy require radiotherapy nodal positivity Completed plan chemotherapy schedule ER and/or PR positive patient Patients decide put tamoxifen Patients reliable follow Patients BCT pT1 pT2 breast lesion ( N0 , N1 ) Patients palliative radiotherapy chest wall/breast/supraclavicular fossa Any patient require radiation axillary internal mammary area Recurrent disease metastatic disease Patients concurrent chemotherapy radiation</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Pulmonary fibrosis</keyword>
	<keyword>tamoxifen</keyword>
	<keyword>radiotherapy</keyword>
</DOC>